The registration phase 3 HER2CLIMB trial studied the addition of tucatinib or placebo to trastuzumab–capecitabine in patients with metastatic HER2+ breast cancer and had a prespecified endpoint of activity in HER2+ BCBM [15]. The gene discussed is ERBB2; the disease is breast carcinoma.